Wall Street Zen Upgrades China SXT Pharmaceuticals (NASDAQ:SXTC) to "Hold"

Key Points

• Wall Street Zen has upgraded China SXT Pharmaceuticals (NASDAQ:SXTC) from a "sell" rating to a "hold" rating in a recent report.
• The stock opened at $1.70 on Friday, with a 12-month range of $0.95 to $8.72.
• China SXT Pharmaceuticals specializes in the research, development, and sale of traditional Chinese medicine products in China.

China SXT Pharmaceuticals (NASDAQ:SXTC - Get Free Report) was upgraded by Wall Street Zen from a "sell" rating to a "hold" rating in a report issued on Saturday.

China SXT Pharmaceuticals Stock Down 7.1%

SXTC stock traded down $0.12 on Friday, hitting $1.58. The company had a trading volume of 76,846 shares, compared to its average volume of 1,956,184. The company has a current ratio of 3.54, a quick ratio of 3.40 and a debt-to-equity ratio of 0.01. The stock's 50-day simple moving average is $1.70 and its 200 day simple moving average is $2.42. China SXT Pharmaceuticals has a 12-month low of $0.95 and a 12-month high of $8.64.

About China SXT Pharmaceuticals

China SXT Pharmaceuticals, Inc, a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen.